Delstrigo

DRUG2 trials

Sponsors

Hospital Clinic of Barcelona, Professor Francois Venter

Conditions

HIV-1-infectionHiv

Phase 3

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Active, not recruitingNCT05924438

Professor Francois VenterHIV-1-infection

Start: 2023-11-08End: 2026-06-30Updated: 2025-04-02

Phase 4

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

CompletedNCT04233372

Hospital Clinic of BarcelonaHiv

Start: 2020-08-27End: 2022-07-28Updated: 2025-09-10

Related Papers

Initial HIV Therapy for Adults and Treatment-Associated Weight Gain

JAMA2026-07-31

Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes2025-01-031 citations

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)

Open Forum Infectious Diseases2023-07-19